Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Abstract The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why...

Full description

Bibliographic Details
Main Authors: Thomas McFall, Michael Trogdon, Anita C. Guizar, John F. Langenheim, Laura Sisk-Hackworth, Edward C. Stites
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-022-00329-w

Internet

https://doi.org/10.1038/s41698-022-00329-w

Similar Items